IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Orexigen Therapeutics Inc

CUSIP: 686164AA2 | 20 institutional holders

Quarters

Q3 2014Q2 2014Q1 2014Q4 2013
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q3 2014

Advent Capital Management20,622,000
0.2% of portfolio›$18.8K
StyleTurnoverLocationFiled
Advent Capital Management
20,622,000$18.8K0.2%GrowthMediumNew York, NY2014-11-14